


Dear author,

Please note that changes made in the online proofing system will be added to the article before publication but are not reflected in this PDF.

We also ask that this file not be used for submitting corrections.

AUTHOR QUERY FORM

	Journal: JCYT Article Number: 824	Please e-mail your responses and any corrections to: E-mail: corrections.esi@elsevier.toppanbestset.com
---	--	--

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

We were unable to process your file(s) fully electronically and have proceeded by

Scanning (parts of) your article Rekeying (parts of) your article Scanning the artwork

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the '[Q](#)' link to go to the location in the proof.

Location in article	Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof		
Q1	Please confirm that given names and surnames have been identified correctly and are presented in the desired order and please carefully verify the spelling of all authors' names.		
Q2	Please check this website address and confirm that it is correct. (Please note that it is the responsibility of the author(s) to ensure that all URLs given in this article are correct and useable.)		
	<table border="1" style="margin-left: auto; margin-right: auto;"> <tr> <td data-bbox="539 1262 1198 1339" style="color: red; text-align: center;">Please check this box or indicate your approval if you have no corrections to make to the PDF file</td> <td data-bbox="1198 1262 1294 1339" style="width: 50px; height: 30px;"></td> </tr> </table>	Please check this box or indicate your approval if you have no corrections to make to the PDF file	
Please check this box or indicate your approval if you have no corrections to make to the PDF file			

Thank you for your assistance.

Regenerative medicine in hearing recovery

EDI SIMONTI¹, GIULIA ORSINI², MILVIA CHICCA³, SIMONE BETTINI⁴,
VALERIA FRANCESCHINI^{4,5}, ALESSANDRO MARTINI^{1,5} & LAURA ASTOLFI^{1,5}

¹Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy, ²Auromet srl, Pisa, Italy, ³Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy, ⁴Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy, and ⁵Foundation Onlus Staminali e Vita, Padua, Italy

Abstract

Hearing loss, or deafness, affects 360 million people worldwide of which about 32 million are children. Deafness is irreversible when it involves sensory hair cell death because the regenerative ability of these cells is lost in mammals after embryo development. The therapeutic strategies for deafness include hearing aids and/or implantable devices. However, not all patients are eligible or truly benefit from these medical devices. Regenerative medicine based on stem cell application could play a role in both improvement of extant medical devices and *in vivo* recovery of auditory function by regeneration of inner ear cells and neurons. A review of recent literature on the subject indicates that two promising approaches to renewal and differentiation of cochlear tissues are transplantation of stem cells and *in situ* administration of growth factors. Rather than directly regenerating dead cells, these procedures apparently induce, through various pathways, differentiation of resident cochlear cells. More studies on the possible adverse effects of transplanted cells and the recovery of tonotopic sensorineural activity or required. To date, no reliable clinical results have been obtained in the field of cochlear regeneration.

Key Words: Cochlear stem cells, endogenous stem cells, growth factor supplements, hearing loss, hearing recovery, inner ear, stem cell transplantation

Introduction

Worldwide, the majority of hearing disabilities (approximately 90%) result from the death of sensory cells, either hair cells (HCs) or spiral ganglion neurons (SGNs), thus leading to sensorial and/or neural hearing loss (SNHL). The etiology of SNHL includes mainly ototoxicity, deafening noise and presbycusis [1,2]. Impairment due to SNHL has significant social and economic impact because it affects the ability to interact with people and the surrounding environment and, when it occurs early in life, causes language development delays and social integration problems [3,4].

The cochlear implant is the unique surgical option for people with severe-to-profound SNHL. This electronic high-technology device transforms sound waves into an electric stimulus, bypassing the damaged cochlear cells to directly stimulate the acoustic nerve. However, even with recent advances in engineering, surgery and pharmaceutical treatments that have improved the efficacy of cochlear implants and reduced electrode insertion trauma, normal auditory function

cannot be completely restored [5,6]. New therapeutic strategies based on molecular, cellular and nanotechnological tools are aimed at regenerating and/or preserving sensory cells in the cochlea, contributing to improved cochlear implant outcomes [7–9]. Studies on nanotechnological tools involve the development of nanostructured electrodes and the improvement of drug delivery systems based on nanoparticles [10–12]. Regenerative medicine, an intriguing therapeutic strategy, has been successful in several research and clinical fields, such as dermatology, cardiovascular medicine and orthopedics [13]. Among regenerative medicine strategies, the use of stem cells (SCs) to restore damaged tissues is one of the most studied cell-based applications [14]. In otology, for example, SCs transplanted on synthetic scaffolds have recently been applied in tissue engineering for reconstruction of the human auricle [15,16]. The aim of SC-based therapy in SNHL is to replace lost HCs or SGNs, and the major challenge is to achieve this without affecting the complex cytoarchitecture of the cochlea and any residual hearing function [17,18].

Correspondence: Laura Astolfi, PhD, Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, via G. Orus, 2b, 35129 Padua, Italy. E-mail: laura.astolfi@unipd.it

(Received 20 January 2017; accepted 21 April 2017)

ISSN 1465-3249 Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
<http://dx.doi.org/10.1016/j.jcyt.2017.04.008>

This review highlights the state of the art in regenerative medicine of inner-ear cells, discussing recent applications in hearing disabilities. Two general approaches are commonly used for tissue regeneration based on SCs: tissue-resident SCs or transplanted allogeneic SCs. The review focuses first on cochlear-resident putative SCs and then on *in vitro* production of HCs and SGNs. Finally, it considers *in vivo* tissue regeneration by transplantation of allogeneic SCs and/or growth factor supplementation for neuronal regrowth and protection.

Cochlear SCs

The identification of neural SCs (NSCs) in the adult central nervous system [19] and the well-known capability of injured non-mammalian adult vertebrates to restore damaged auditory sensory epithelium [20] encouraged researchers to investigate whether SCs could also be located in the mammalian inner ear and whether their regenerative ability could also be exploited in mammalian tissues.

In inner ear, a small number of SCs were isolated from adult mouse utricles, amounting to 0.025% of utricular cells [21]. Later, several studies identified and isolated SCs from mammalian cochlear sensory epithelium, spiral ganglion and stria vascularis of early postnatal mice, rats, guinea pigs and human fetuses [22–26]. These cells form self-renewing spheres in non-adherent cultures, but this ability weakens after several *ex vivo* passages [27]. When isolated from the cochlear sensory epithelium, these SCs are also able to differentiate into inner ear cell lineages, such as HC-like cells and sensory neurons, and into mature neurons and glia cells when isolated from the spiral ganglion [28,29].

In mice, the ability of sensory epithelial SCs to form spheres decreases about 100-fold during the second and third postnatal week, together with the expression of developmental and progenitor cell markers in the cochlea [21]. In contrast, utricle SCs maintain these characteristics into adulthood [20,21]. There is only one report concerning isolation of NSCs from adult human and guinea pig spiral ganglion [30].

Over the past few years, there has been evidence indicating that postnatal cochlear supporting cells also maintain SC-like characteristics in mammals [31] and are able to divide and trans-differentiate *in vitro* into HCs [32]. These abilities decline with age [33]: in cochlear SCs forming spheres, this decline is partially caused by changes in the expression of the cyclin-dependent kinase inhibitor (Cdkn1b), which plays a central role in regulating cell proliferation. After HC formation, the expression of Cdkn1b in the organ of Corti is restricted to non-sensory cells, preventing further divisions of HCs [33,34]. Moreover,

p27-deficient mice exhibit hearing damage due to the over-proliferation and irregular positioning of both hair and supporting cells [35]. Another key gene involved in HC differentiation is *ATOH1* (atonal bHLH transcription factor 1), also known as *MATH1* (mouse atonal homolog 1) [36,37]. It has been shown that transfection of *ATOH1* *in vivo* after acoustic trauma induces its over-expression in supporting cells, promoting their differentiation in HCs and hearing recovery [36,37]. A known marker of adult SC, *Lgr5*, has been used to verify that supporting cells are the progenitors of HC: *Lgr5*⁺ supporting cells isolated from neonatal mice were able to form self-renewing neurospheres and differentiate into *myo7a*⁺ HCs both *in vitro* and *in vivo* [38]. These observations are supported by those obtained on avian models, where adult supporting cells maintain their ability to differentiate into HCs, replacing them after a cochlear damage [39,40]. Other authors maintain that putative cochlear SCs may derive from the mesenchymal SCs (MSCs) reservoir located in the inner ear stroma underlying the epithelial tissue [41]. Although it remains unclear, some studies have shown that MSCs are able to differentiate *in vitro* in both HC-like cells and neurons [42,43].

In vitro regeneration by SCs

Transplantation of SCs to restore damaged inner ear cells and restore hearing function is an emerging field of research because mammalian HCs and SGNs are unable to regenerate after cell death resulting from trauma, disease or genetic mutation [7,44].

HCs and SGNs have been obtained *in vitro* from several types of SCs, including bone marrow MSCs (BM-MSCs), adipose-derived MSC (ASCs), olfactory precursor cells, embryonic SCs and adult brain germinal zone-derived cells (NSCs) from mice, rats and humans [45–52]. Despite these data, the ability of MSCs to differentiate into HCs and neurons is still controversial. Induced pluripotent SCs (iPSs) from mice were induced to become otic progenitors by exposure to growth factors, producing functionally active HCs [53]. Several authors investigated the possibility of obtaining new HCs and SGNs from endogenous sources and from putative cochlea-resident SCs. New functional sensory epithelia were obtained from endogenous avian inner ear cells by mesenchymal-to-epithelial transition after several culture freezing and expansion cycles, without co-culture with other tissues [54]. Isolated SGNs have been shown to be able to survive *in vitro*, forming synapses with other neurons and HC in co-culture [48]. In *in vitro* co-cultures, also the neural progenitors derived from embryonic SCs were able to regenerate the complex neural network of the inner ear by producing neurites (positive to synaptic markers) elongating toward HCs [43,47,55,56]. These *in vitro*

184 data were supported by *in vivo* studies of embryonic
185 SC transplantation after cochlea denervation
186 [42,47,55–59].

187 *In vivo* regeneration by SCs

189 Cochlea-resident endogenous SCs may represent
190 the main source for inner ear cell repair, but no evi-
191 dence of their ability to generate new HCs or neurons
192 as physiological responses to auditory injuries is
193 currently available. The use of exogenous sources for
194 SC transplantation in SNHL has been established,
195 however. Several studies have investigated transplan-
196 tation of SCs isolated from various tissues into the
197 damaged cochlea to increase HC and/or SGN number
198 and function, thus restoring auditory capability. In some
199 of these studies, NSCs or *in vitro* neural-differentiated
200 exogenous SCs (ExSCs) were transplanted via topic
201 administration into cochleae with pharmacological or
202 physical damage; results indicated survival of injec-
203 ted cells, an increased number of target cells, partial
204 SC differentiation into neurons and/or glial cells, and,
205 in some cases, improved hearing function [60–65].
206 Sakamoto *et al.* [66] transplanted undifferentiated
207 mouse ExSCs into neomycin-treated mouse and em-
208 bryonic chicken inner ears. Some ExSCs developed
209 into ectoderm cells but not into HCs in mice, and in
210 chickens, these cells were driven into neural crest cells,
211 next to the otic vesicles. However, Zheng *et al.* [67]
212 isolated cochlear SCs from newborn rats and trans-
213 planted them into the scala tympani of gentamicin-
214 deafened rats, showing a migration of transplanted
215 HC-like cells from the injection site to the basal mem-
216 brane and organ of Corti with hearing recovery. Other
217 studies showed that transplanted SCs could survive
218 at the injection site, regardless of the presence of an
219 external acoustic damage [68–70]. Kasagi *et al.* [68]
220 investigated the ability of young and old mice to accept
221 mouse BM-MSC transplantation into the perilymph,
222 showing a positive engraftment only in young indi-
223 viduals, with no adverse effects on auditory brainstem
224 response (ABR) test in both groups. The recovery of
225 auditory function in mice with age-related hearing loss
226 by transplantation of human adult olfactory SCs into
227 the cochlea was investigated by Pandit *et al.* [69], who
228 found that transplanted cells could survive in coch-
229 lear tissue and improve hearing function, although
230 they did not integrate in the tissue [69]. Embryonic
231 rat NSCs transfected with *ATOH1* gene were trans-
232 planted into normal guinea pig cochleae by Han *et al.*
233 [70]. All NSCs survived; approximately 10% differ-
234 entiated into HCs in the cochlear epithelium and more
235 than 10% into neurons in the endolymphatic space.

236 Another target for SC therapy in SNHL is the cochlear
237 lateral wall because hearing loss is also known
238 to be caused by mutations of genes encoding for

239 gap-junction proteins [71–75]. These molecular altera-
240 tions have been studied in the stria vascularis [71],
241 in otic fibrocytes [72] and in age-related or damage-
242 induced fibrocyte degeneration in the spiral ligament
243 [73,74]. Kasagi *et al.* [68] and Kamiya *et al.* [75] re-
244 ported transplanted rat BM-MSCs in the perilymph
245 of a SNHL rat model with a lateral wall fibrocyte dys-
246 function not associated with changes in the organ of
247 Corti. Transplanted cells found in the injured area
248 could express connexin 26 and connexin 30, indicat-
249 ing a reactivation of gap junction between neighboring
250 cells. Moreover, the transplanted rat group showed a
251 higher hearing recovery ratio than controls [75]. Other
252 studies have shown that intravenously transplanted BM-
253 MSCs and hematopoietic SCs (HSCs) in mice were
254 able to integrate in the cochlea and differentiate into
255 mesenchymal cells, including fibrocytes, suggesting a
256 continuous turnover from the HSC reservoir [76].

257 Despite these encouraging results in SC trans-
258 plantation for SNHL therapy, several issues are still
259 unresolved. First, only a few studies have evaluated
260 the functional recovery associated to the engraftment
261 of transplanted SCs and the repopulation of damaged
262 tissues, and in some of these, there were no significant
263 differences compared with control groups [61,77]. These
264 results could be partially ascribed to the insufficient
265 formation of functional synapses between the new HC
266 population and the surviving neurons [61,77]. On the
267 basis of SC transplantation studies, cell regeneration
268 appears unrelated to a direct ExSC differentiation into
269 the depleted cell population, but rather to damage
270 recover by activation of the reservoir of unaffected en-
271 dogenous SCs through release of cytokines and growth
272 factors by ExSCs [78–80]. Because the use of ExSCs
273 and NSCs entails relevant issues concerning ethics
274 and availability, some studies investigated the use of
275 MSCs or SCs from other sources for inner ear cell
276 therapy, as previously described. Mesenchymal and ep-
277 ithelial SCs have been shown to be recruited, survive
278 and engraft into the injured area, in some cases ex-
279 pressing specific differentiation markers [75,77,81].
280 Cho *et al.* [82] used human BM-MSCs *in vitro* neural-
281 differentiated to treat a guinea pig animal model with
282 ouabain-induced auditory neuropathy. By injecting
283 BM-MSCs in the scala tympani, they showed an in-
284 crease in SGN number, some of them human-derived,
285 associated with the improvement of hearing function
286 [82]. Similar results were obtained by human embryonic
287 SCs induced to differentiate *in vitro* into hair cells and
288 auditory neurons: when transplanted into an auditory
289 neuropathy model, these cells significantly improved
290 hearing recovery [50]. Other authors used HSCs to
291 treat HC death after transient cochlear ischemia in
292 gerbils. These cells prevented HC degeneration and
293 improved hearing function but did not transdifferentiate
294 or fuse with endogenous cells, suggesting a paracrine

effect as the mechanism of action in HC repair [82]. Revoltella *et al.* [17] transplanted human umbilical cord blood (UCB) CD133⁺ hematopoietic SCs intravenously into oto-injured mice and observed the recruitment of these ExSCs to the damaged ear tissue, morphologic recovery of the organ of Corti and a small number of heterokaryons, probably derived from fusion events between donor and endogenous cells. These heterokaryons could play an active role in the repair process [17]. Based on this study, a phase 1/2 clinical trial was initiated in 2014 in the United States on children with acquired hearing loss, who received a single dose of autologous UCB SCs via intravenous infusion ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02038972) identifier: NCT02038972). The clinical trial is still in process, but the main expected outcome is an evaluation of safety and feasibility of UCB transplantation, possibly with improvement of inner ear function, audition and language development as secondary effect [83].

***In vivo* regeneration by growth factors**

Another strategy for HC regeneration involves the administration of growth factors, which may protect from degeneration and/or restore HCs and SGNs. The growth factors most suitable for this task are the neurotrophic factors (NTFs), especially neurotrophin-3 (NT-3) and brain-derived neurotrophic factor (BDNF).

During embryonic development in rats and mice, NT-3 was expressed in supporting cells at higher levels than in HCs [84]; after birth, it was higher in HCs but generally declined postnatally, although a partial expression remained in adult mice, mainly in inner HCs, but also in SGNs, glia and supporting cells [85,86]. NT-3 follows two expression gradients, one along the tonotopic axis (highest in the cochlear base, lowest in the apex), the other from the inner to the outer areas (higher in inner HCs, lowest in outer HCs) [86]. BDNF was also expressed in the organ of Corti during the embryonic development in rats and mice, but, in contrast to NT-3, its expression was highest in the cochlear apex, lowest at the base and equal in inner and outer HCs [87].

The BDNF expression declined prenatally and was at very low levels at postnatal day 1 (P1) but transiently increased between P4 and P9. BDNF mRNA was also found in HCs in adult mice [87], although at low levels. Other neurotrophins were found to be expressed in the cochlea; for example, in HCs of adult mice, the mRNA levels of glial-derived neurotrophic factor (GDNF) was higher than those of NT-3, and ciliary neurotrophic factor (CNTF) was also expressed in the spiral ganglion [88]. Concerning their receptors (tropomyosin receptor kinases, Trk), the TrkB (a receptor of BDNF) and TrkC (receptor of NT-3) were shown to still be expressed in the postnatal SGNs,

increasing neuronal metabolism and survival and promoting neurite outgrowth [89]. On the basis of these results, other groups investigated the ability of NTF to repair damages in the organ of Corti by cell preservation and neural network regeneration, thus preventing further degeneration and restoring the auditory function. The *in vitro* and *in vivo* treatment with NTF, supplemented with CNTF, GDNF, insulin growth factor-1 (IGF-1) or macrophage migration inhibitory factor, was able to promote SGN survival, neurite outgrowth, synaptogenesis and re-innervation of the sensory area [90–95].

The route of *in vivo* administration of growth factors is a highly debated issue. Most studies administered the growth factors locally, via mini-osmotic pumps, but a long-term delivery would be more suitable because neurotrophins have a short serum half-life. To ensure a long-term and more cell-targeted release, some studies used adenoviruses or viral vectors [96,97] or cell-based delivery [98–101]. To obtain a sustained topical release, another route of administration was devised by placing biodegradable hydrogels soaked with IGF-1 [33,102,103]. This protocol was also adopted for a clinical trial in which 25 patients affected by sudden sensorineural hearing loss and glucocorticoid resistance were treated with IGF-1-soaked gelatine hydrogels, intra-tympanically applied in the middle ear. The results showed that 48% and 56% of patients had hearing improvement 12 and 24 weeks after treatment, respectively, without adverse effects [104].

Perspectives

In conclusion, evidence of tissue-resident endogenous SCs in the inner ear raises the possibility of using these cells in SNHL by promoting their *in vivo* differentiation to replace damaged cells and restore cochlear morphology and function. At present, the *in vitro* and *in vivo* induction of resident cochlear cell differentiation is a promising procedure in regenerative therapy. More studies are nevertheless required to clarify the outcome of transplanted cells and avoid tumor development and to understand how to restore connections between the SGNs and HCs to recover the tonotopic sensorineural activity.

With regard to cochlear regeneration, significant progress has recently been made in understanding the molecular bases of inner ear development, and *in vitro* and *in vivo* models of inner ear regenerative medicine have been established. However, reliable results for cochlear regeneration have not yet been attained in clinical practice.

Acknowledgment

We thank Dr. Barbara Zavan and Dr. Filippo Valente for preliminary manuscript review and suggestions.

This work was supported by the Italian Ministry of Education, University and Research (MIUR), grant PRIN- 2010S58B38_004.

Disclosure of interest: The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.

References

- [1] Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. *Anat Rec (Hoboken)* 2012;295:1837–50.
- [2] Seixas NS, Neitzel R, Stover B, Sheppard L, Feeney P, Mills D, et al. 10-Year prospective study of noise exposure and hearing damage among construction workers. *Occup Environ Med* 2012;69:643–50.
- [3] Ciorba A, Martini A. Regeneration in the mammalian inner ear: a glimpse into the future. *Hearing Balance Commun* 2014;12:1–5.
- [4] Martini A, Castiglione A, Bovo R, Vallesi A, Gabelli C. Aging, cognitive load, dementia and hearing loss. *Audiol Neurootol* 2014;19:2–5.
- [5] Ciorba A, Astolfi L, Jolly C, Martini A. Cochlear implants and inner ear based therapy. *Eur J Nanomed* 2009;2:25–8.
- [6] Okano T, Kelley MW. Stem cell therapy for the inner ear: recent advances and future directions. *Trends Amplif* 2012;16:4–18.
- [7] Ciorba A, Astolfi L, Martini A. Otoprotection and inner ear regeneration. *Audiol Med* 2008;6:170–5.
- [8] Giordano P, Hatzopoulos S, Giarbini N, Prosser S, Petrucelli J, Simoni E, et al. A soft-surgery approach to minimize hearing damage caused by the insertion of a cochlear implant electrode: a guinea pig animal model. *Otol Neurotol* 2014;35:1440–5.
- [9] Schendzielorz P, Scherzed A, Rak K, Völker J, Hagen R, Mlynski R, et al. A hydrogel coating for cochlear implant arrays with encapsulated adipose-derived stem cells allows brain-derived neurotrophic factor delivery. *Acta Otolaryngol* 2014;134:497–505.
- [10] Petit-Zeman S. Regenerative medicine. *Nat Biotechnol* 2001;19:201–6.
- [11] Teo AK, Vallier L. Emerging use of stem cells in regenerative medicine. *Biochem J* 2010;428:11–23.
- [12] Golas AR, Hernandez KA, Spector JA. Tissue engineering for plastic surgeons: a primer. *Aesthetic Plast Surg* 2014;38:207–21.
- [13] Wallace GG, Higgins MJ, Moulton SE, Wang C. Nanobionics: the impact of nanotechnology on implantable medical bionic devices. *Nanoscale* 2012;4:4327–47.
- [14] Li L, Chao T, Brant J, O'Malley B Jr, Tsourkas A, Li D. Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss. *Adv Drug Deliv Rev* 2017;108:2–12.
- [15] Valente F, Astolfi L, Simoni E, Danti S, Franceschini V, Chicca M, et al. Nanoparticle drug delivery systems for inner ear therapy: an overview. *J Drug Deliv Sci Technol* 2017;39:28–35.
- [16] Villar-Fernandez MA, Lopez-Escamez JA. Outlook for tissue engineering of the tympanic membrane. *Audiol Res* 2015;5:117.
- [17] Revoltella RP, Papini S, Rosellini A, Michelini M, Franceschini V, Ciorba A, et al. Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. *Cell Transplant* 2008;17:665–78.
- [18] Gunewardene N, Dottori M, Nayagam BA. The convergence of cochlear implantation with induced pluripotent stem cell therapy. *Stem Cell Rev* 2012;8:741–54.
- [19] Bonaguidi MA, Peng CY, McGuire T, Falciglia G, Gobeske KT, Czeisler C, et al. Noggin expands neural stem cells in the adult hippocampus. *J Neurosci* 2008;28:9194–204.
- [20] Namdaran P, Reinhart KE, Owens KN, Raible DW, Rubel EW. Identification of modulators of hair cell regeneration in the zebrafish lateral line. *J Neurosci* 2012;32:3516–28.
- [21] Li H, Liu H, Heller S. Pluripotent stem cells from the adult mouse inner ear. *Nat Med* 2003;9:1293–9.
- [22] Oshima K, Grimm CM, Corrales CE, Senn P, Martinez Monedero R, Géléoc GS, et al. Differential distribution of stem cells in the auditory and vestibular organs of the inner ear. *J Assoc Res Otolaryngol* 2007;8:18–31.
- [23] Chen W, Johnson SL, Marcotti W, Andrews PW, Moore HD, Rivolta MN. Human fetal auditory stem cells can be expanded *in vitro* and differentiate into functional auditory neurons and hair cell-like cells. *Stem Cells* 2009;27:1196–204.
- [24] Diensthuber M, Oshima K, Heller S. Stem/progenitor cells derived from the cochlear sensory epithelium give rise to spheres with distinct morphologies and features. *J Assoc Res Otolaryngol* 2009;10:173–90.
- [25] Rak K, Wasielewski NV, Radeloff A, Völkers J, Scherzed A, Jablonka S, et al. Isolation and characterization of neural stem cells from the neonatal rat cochlear nucleus. *Cell Tissue Res* 2011;343:499–508.
- [26] Chao TT, Wang CH, Chen HC, Shih CP, Sytwu HK, Huang KL, et al. Adherent culture conditions enrich the side population obtained from the cochlear modiolus-derived stem/progenitor cells. *Int J Pediatr Otorhinolaryngol* 2013;77:779–84.
- [27] Lou XX, Nakagawa T, Ohnishi H, Nishimura K, Ito J. Otophores derived from neonatal mouse cochlea retain the progenitor cell phenotype after ex vivo expansions. *Neurosci Lett* 2013;534:18–23.
- [28] Martinez-Monedero R, Yi E, Oshima K, Glowatzki E, Edge AS. Differentiation of inner ear stem cells to functional sensory neurons. *Dev Neurobiol* 2008;68:669–84.
- [29] Oshima K, Senn P, Heller S. Isolation of sphere-forming stem cells from the mouse inner ear. *Methods Mol Biol* 2009;493:141–62.
- [30] Rask-Andersen H, Boström M, Gerdin B, Kinnefors A, Nyberg G, Engstrand T, et al. Regeneration of human auditory nerve. In vitro/in vivo demonstration of neural progenitor cells in adult human and guinea pig spiral ganglion. *Hear Res* 2005;203:180–91.
- [31] Monzack EL, Cunningham LL. Lead roles for supporting actors: critical functions of inner ear supporting cells. *Hear Res* 2013;303:20–9.
- [32] White PM, Doetzlhofer A, Lee YS, Groves AK, Segil N. Mammalian cochlear supporting cells can divide and trans-differentiate into hair cells. *Nature* 2006;441:984–7.
- [33] Fujioka M, Okano H, Edge AS. Manipulating cell fate in the cochlea: a feasible therapy for hearing loss. *Trends Neurosci* 2015;38:139–44.
- [34] Löwenheim H, Furness DN, Kil J, Zinn C, Gültig K, Fero ML, et al. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti. *Proc Natl Acad Sci USA* 1999;96:4084–8.
- [35] Kanzaki S, Beyer LA, Swiderski DL, Izumikawa M, Stöver T, Kawamoto K, et al. p27(Kip1) deficiency causes organ of Corti pathology and hearing loss. *Hear Res* 2006;214:28–36.

- 536 [36] Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. *Nat Med* 2005;11:271–6. 603
- 537 [37] Mizutari K, Fujioka M, Hosoya M, Bramhall N, Okano HJ, Okano H, et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. *Neuron* 2013;77(1):58–69. Correction in: *Neuron* 2013;78:403. 604
- 538 [38] Shi F, Kempfle JS, Edge AS. Wnt-responsive Lgr5-expressing stem cells are hair cell progenitors in the cochlea. *J Neurosci* 2012;32:9639–48. 605
- 539 [39] Bird JE, Daudet N, Warchol ME, Gale JE. Supporting cells eliminate dying sensory hair cells to maintain epithelial integrity in the avian inner ear. *J Neurosci* 2010;30:12545–56. 606
- 540 [40] Kuo BR, Baldwin EM, Layman WS, Taketo MM, Zuo J. *In vivo* cochlear hair cell Generation and survival by coactivation of β -catenin and Atoh1. *J Neurosci* 2015; 35:10786–98. 607
- 541 [41] Groves AK. The challenge of hair cell regeneration. *Exp Biol Med (Maywood)* 2010;235:434–46. 608
- 542 [42] Kondo T, Matsuoka AJ, Shimomura A, Koehler KR, Chan RJ, Miller JM, et al. Wnt signaling promotes neuronal differentiation from mesenchymal stem cells through activation of Tlx3. *Stem Cells* 2011;29:836–46. 609
- 543 [43] Boddy SL, Chen W, Romero-Guevara R, Kottam L, Bellantuono I, Rivolta MN. Inner ear progenitor cells can be generated in vitro from human bone marrow mesenchymal stem cells. *Regen Med* 2012;7:757–67. 610
- 544 [44] Tan BT, Lee MM, Ruan R. Bone-marrow-derived cells that home to acoustic deafened cochlea preserved their hematopoietic identity. *J Comp Neurol* 2008;509:167–79. 611
- 545 [45] Lang H, Xing Y, Brown LN, Samuvel DJ, Panganiban CH, Havens LT, et al. Neural stem/progenitor cell properties of glial cells in the adult mouse auditory nerve. *Sci Rep* 2015;5:13383. 612
- 546 [46] Jeon SJ, Oshima K, Heller S, Edge AS. Bone marrow mesenchymal stem cells are progenitors in vitro for inner ear hair cells. *Mol Cell Neurosci* 2007;34:59–68. 613
- 547 [47] Coleman B, Fallon JB, Pettingill LN, de Silva MG, Shepherd RK. Auditory hair cell explant co-cultures promote the differentiation of stem cells into bipolar neurons. *Exp Cell Res* 2007;313:232–43. 614
- 548 [48] Wei D, Jin Z, Järleback L, Scarfone E, Ulfendahl M. Survival, synaptogenesis, and regeneration of adult mouse spiral ganglion neurons *in vitro*. *Dev Neurobiol* 2007;67:108–22. 615
- 549 [49] Qin H, Zhao LD, Sun JH, Ren LL, Guo WW, Liu HZ, et al. The differentiation of mesenchymal stem cells into inner ear hair cell-like cells *in vitro*. *Acta Otolaryngol* 2011;131:1136–41. 616
- 550 [50] Chen W, Jongkamonwiwat N, Abbas L, Eshtan SJ, Johnson SL, Kuhn S, et al. Restoration of auditory evoked responses by human ES-cell-derived otic progenitors. *Nature* 2012; 490:278–82. 617
- 551 [51] Bas E, Van De Water TR, Lumberras V, Rajguru S, Goss G, Hare JM, et al. Adult human nasal mesenchymal-like stem cells restore cochlear spiral ganglion neurons after experimental lesion. *Stem Cells Dev* 2014;23:502–14. 618
- 552 [52] Koehler KR, Mikosz AM, Molosh AI, Patel D, Hashino E. Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. *Nature* 2013;500:217–21. 619
- 553 [53] Oshima K, Shin K, Diensthuber M, Peng AW, Ricci AJ, Heller S. Mechanosensitive hair cell-like cells from embryonic and induced pluripotent stem cells. *Cell* 2010;141:704–16. 620
- 554 [54] Hu Z, Corwin JT. Inner ear hair cells produced in vitro by a mesenchymal-to-epithelial transition. *Proc Natl Acad Sci USA* 2007;104:16675–80. 621
- 555 [55] Kim TS, Nakagawa T, Kita T, Higashi T, Takebayashi S, Matsumoto M, et al. Neural connections between embryonic stem cell-derived neurons and vestibular hair cells *in vitro*. *Brain Res* 2005;1057:127–33. 622
- 556 [56] Nayagam BA, Edge AS, Needham K, Hyakumura T, Leung J, Nayagam DA, et al. An *in vitro* model of developmental synaptogenesis using cocultures of human neural progenitors and cochlear explants. *Stem Cells Dev* 2013;22:901–12. 623
- 557 [57] Li H, Roblin G, Liu H, Heller S. Generation of hair cells by stepwise differentiation of embryonic stem cells. *Proc Natl Acad Sci USA* 2003;100:13495–500. 624
- 558 [58] Shi F, Corrales CE, Liberman MC, Edge AS. BMP4 induction of sensory neurons from human embryonic stem cells and reinnervation of sensory epithelium. *Eur J Neurosci* 2007;26:3016–23. 625
- 559 [59] Lin Z, Perez P, Sun Z, Liu JJ, Shin JH, Hyrc KL, et al. Reprogramming of single-cell-derived mesenchymal stem cells into hair cell-like cells. *Otol Neurotol* 2012;33:1648–55. 626
- 560 [60] Hu Z, Wei D, Johansson CB, Holmström N, Duan M, Frisén J, et al. Survival and neural differentiation of adult neural stem cells transplanted into the mature inner ear. *Exp Cell Res* 2005;302:40–77. 627
- 561 [61] Hildebrand MS, Dahl HH, Hardman J, Coleman B, Shepherd RK, de Silva MG. Survival of partially differentiated mouse embryonic stem cells in the scala media of the guinea pig cochlea. *J Assoc Res Otolaryngol* 2005;6:341–54. 628
- 562 [62] Coleman B, Hardman J, Coco A, Epp S, de Silva M, Crook J, et al. Fate of embryonic stem cells transplanted into the deafened mammalian cochlea. *Cell Transplant* 2006;15:369–80. 629
- 563 [63] Corrales CE, Pan L, Li H, Liberman MC, Heller S, Edge AS. Engraftment and differentiation of embryonic stem cell-derived neural progenitor cells in the cochlear nerve trunk: growth of processes into the organ of Corti. *J Neurobiol* 2006;66:1489–500. 630
- 564 [64] Parker MA, Corliss DA, Gray B, Anderson JK, Bobbin RP, Snyder EY, et al. Neural stem cells injected into the sound-damaged cochlea migrate throughout the cochlea and express markers of hair cells, supporting cells, and spiral ganglion cells. *Hear Res* 2007;232:29–43. 631
- 565 [65] Lang H, Schulte BA, Goddard JC, Hedrick M, Schulte JB, Wei L, et al. Transplantation of mouse embryonic stem cells into the cochlea of an auditory-neuropathy animal model: effects of timing after injury. *J Assoc Res Otolaryngol* 2008; 9:225–40. 632
- 566 [66] Sakamoto T, Nakagawa T, Endo T, Kim TS, Iguchi F, Naito Y, et al. Fates of mouse embryonic stem cells transplanted into the inner ears of adult mice and embryonic chickens. *Acta Otolaryngol Suppl* 2004;551:48–52. 633
- 567 [67] Zheng H, Tai H, Zeng S. Cochlear stem cell transplantation for hearing recovery in a rat model of sensorineural hearing loss. *Neural Regen Res* 2010;5:833–7. 634
- 568 [68] Kasagi H, Kuhara T, Okada H, Sueyoshi N, Kurihara H. Mesenchymal stem cell transplantation to the mouse cochlea as a treatment for childhood sensorineural hearing loss. *Int J Pediatr Otorhinolaryngol* 2013;77:936–42. 635
- 569 [69] Pandit SR, Sullivan JM, Egger V, Borecki AA, Oleskevich S. Functional effects of adult human olfactory stem cells on early-onset sensorineural hearing loss. *Stem Cells* 2011; 29:670–7. 636
- 570 [70] Han Z, Yang JM, Chi FL, Cong N, Huang YB, Gao Z, et al. Survival and fate of transplanted embryonic neural stem cells by Atoh1 gene transfer in guinea pigs cochlea. *Neuroreport* 2010;21:490–6. 637
- 571 [71] Nickel R, Forge A. Gap junctions and connexins in the inner ear: their roles in homeostasis and deafness. *Curr Opin Otolaryngol Head Neck Surg* 2008;16:452–7. 638

- 670 [72] Trowe MO, Maier H, Schweizer M, Kispert A. Deafness in
671 mice lacking the T-box transcription factor Tbx18 in otic
672 fibrocytes. *Development* 2008;135:1725–34. 737
- 673 [73] Spicer SS, Schulte BA. Spiral ligament pathology in quiet-
674 aged gerbils. *Hear Res* 2002;172:172–85. 738
- 675 [74] Hirose K, Liberman MC. Lateral wall histopathology and
676 endocochlear potential in the noise-damaged mouse cochlea.
677 *J Assoc Res Otolaryngol* 2003;4:339–52. 739
- 678 [75] Kamiya K, Fujinami Y, Hoya N, Okamoto Y, Kouike H,
679 Komatsuzaki R, et al. Mesenchymal stem cell transplantation
680 accelerates hearing recovery through the repair of injured
681 cochlear fibrocytes. *Am J Pathol* 2007;171:214–26. 740
- 682 [76] Lang H, Ebihara Y, Schmiedt RA, Minamiguchi H, Zhou
683 D, Smythe N, et al. Contribution of bone marrow hema-
684 topoietic stem cells to adult mouse inner ear: mesenchymal
685 cells and fibrocytes. *J Comp Neurol* 2006;496:187–201. 741
- 686 [77] Choi BY, Song JJ, Chang SO, Kim SU, Oh SH. Intravenous
687 administration of human mesenchymal stem cells after
688 noise- or drug-induced hearing loss in rats. *Acta Otolaryngol*
689 2012;132:S94–102. 742
- 690 [78] Yoshida T, Hakuba N, Morizane I, Fujita K, Cao F, Zhu
691 P, et al. Hematopoietic stem cells prevent hair cell death
692 after transient cochlear ischemia through paracrine effects.
693 *Neuroscience* 2007;145:923–30. 743
- 694 [79] Song M, Heo J, Chun JY, Bae HS, Kang JW, Kang H, et al.
695 The paracrine effects of mesenchymal stem cells stimulate
696 the regeneration capacity of endogenous stem cells in the
697 repair of a bladder-outlet-obstruction-induced overactive
698 bladder. *Stem Cells Dev* 2014;23:654–63. 744
- 699 [80] Santos Nascimento D, Mosqueira D, Sousa LM, Teixeira
700 M, Filipe M, Resende TP, et al. Human umbilical cord
701 tissue-derived mesenchymal stromal cells attenuate
702 remodeling after myocardial infarction by proangiogenic,
703 antiapoptotic, and endogenous cell-activation mechanisms.
704 *Stem Cell Res Ther* 2014;5:5. 745
- 705 [81] Sullivan JM, Cohen MA, Pandit SR, Sahota RS, Borecki AA,
706 Oleskevich S. Effect of epithelial stem cell transplantation
707 on noise-induced hearing loss in adult mice. *Neurobiol Dis*
708 2011;41:552–9. 746
- 709 [82] Cho YB, Cho HH, Jang S, Jeong HS, Park JS.
710 Transplantation of neural differentiated human mesenchymal
711 stem cells into the cochlea of an auditory-neuropathy Guinea
712 pig model. *J Korean Med Sci* 2011;26:492–8. 747
- 713 [83] Clinicaltrials.gov. Safety of autologous stem cell infusion
714 for children with acquired hearing loss [identifier:
715 NCT02038972]. Updated 2016. Available from: [https://
716 clinicaltrials.gov/ct2/show/NCT02038972](https://clinicaltrials.gov/ct2/show/NCT02038972). [Accessed
717 December 2016]. 748
- 718 [84] Fariñas I, Jones KR, Tessarollo L, Vigers AJ, Huang E,
719 Kirstein M, et al. Spatial shaping of cochlear innervation by
720 temporally regulated neurotrophin expression. *J Neurosci*
721 2001;21:6170–80. 749
- 722 [85] Hansen MR, Zha XM, Bok J, Green SH. Multiple distinct
723 signal pathways, including an autocrine neurotrophic
724 mechanism, contribute to the survival-promoting effect of
725 depolarization on spiral ganglion neurons *in vitro*. *J Neurosci*
726 2001;21:2256–67. 750
- 727 [86] Sugawara M, Murtie JC, Stankovic KM, Liberman MC,
728 Corfas G. Dynamic patterns of neurotrophin 3 expression
729 in the postnatal mouse inner ear. *J Comp Neurol* 2007;
730 501:30–7. 751
- 731 [87] Flores-Otero J, Davis RL. Synaptic proteins are tonotopically
732 graded in postnatal and adult type I and type II spiral
733 ganglion neurons. *J Comp Neurol* 2011;519:1455–75. 752
- 734 [88] Stankovic KM, Corfas G. Real-time quantitative RT-PCR
735 for low-abundance transcripts in the inner ear: analysis of
736 neurotrophic factor expression. *Hear Res* 2003;185:97–108. 753
- 737 [89] Green SH, Bailey E, Wang Q, Davis RL. The TrkA, B, C's
738 of neurotrophins in the cochlea. *Anat Rec (Hoboken)*
739 2012;295:1877–95. 740
- 741 [90] Wise AK, Richardson R, Hardman J, Clark G, O'leary S.
742 Resprouting and survival of guinea pig cochlear neurons in
743 response to the administration of the neurotrophins brain-
744 derived neurotrophic factor and neurotrophin-3. *J Comp
745 Neurol* 2005;487:147–65. 746
- 746 [91] Agterberg MJ, Versnel H, van Dijk LM, de Groot JC, Klis
747 SF. Enhanced survival of spiral ganglion cells after cessation
748 of treatment with brain-derived neurotrophic factor in
749 deafened guinea pigs. *J Assoc Res Otolaryngol* 2009;10:355–
750 67. 747
- 751 [92] Bank LM, Bianchi LM, Ebisu F, Lerman-Sinkoff D, Smiley
752 EC, Shen YC, et al. Macrophage migration inhibitory
753 factor acts as a neurotrophin in the developing inner ear.
754 *Development* 2012;139:4666–74. 748
- 755 [93] Hayashi Y, Yamamoto N, Nakagawa T, Ito J. Insulin-like
756 growth factor 1 inhibits hair cell apoptosis and promotes
757 the cell cycle of supporting cells by activating different
758 downstream cascades after pharmacological hair cell injury
759 in neonatal mice. *Mol Cell Neurosci* 2013;56:29–38. 749
- 760 [94] van Loon MC, Ramekers D, Agterberg MJ, de Groot JC,
761 Grolman W, Klis SF, et al. Spiral ganglion cell morphology
762 in Guinea pigs after deafening and neurotrophic treatment.
763 *Hear Res* 2013;298:17–26. 750
- 764 [95] Waaaijer L, Klis SF, Ramekers D, Van Deurzen MH,
765 Hendriksen FG, Grolman W. The peripheral processes of
766 spiral ganglion cells after intracochlear application of
767 brain-derived neurotrophic factor in deafened Guinea pigs.
768 *Otol Neurotol* 2013;34:570–8. 751
- 769 [96] Nakaizumi T, Kawamoto K, Minoda R, Raphael Y.
770 Adenovirus-mediated expression of brain-derived
771 neurotrophic factor protects spiral ganglion neurons from
772 ototoxic damage. *Audiol Neurootol* 2004;9:135–43. 752
- 773 [97] Shibata SB, Cortez SR, Beyer LA, Wiler JA, Di Polo A,
774 Pflugst BE, et al. Transgenic BDNF induces nerve fiber
775 regrowth into the auditory epithelium in deaf cochleae. *Exp
776 Neurol* 2012;223:464–72. 753
- 777 [98] Okano T, Nakagawa T, Kita T, Endo T, Ito J. Cell-gene
778 delivery of brain-derived neurotrophic factor to the mouse
779 inner ear. *Mol Ther* 2006;14:866–71. 754
- 780 [99] Rejali D, Lee VA, Abrashkin KA, Humayun N, Swiderski
781 DL, Raphael Y. Cochlear implants and *ex vivo* BDNF gene
782 therapy protect spiral ganglion neurons. *Hear Res* 2007;
783 228:180–7. 755
- 784 [100] Wise AK, Fallon JB, Neil AJ, Pettingill LN, Geaney MS,
785 Skinner SJ, et al. Combining cell-based therapies and neural
786 prostheses to promote neural survival. *Neurother* 2011;
787 8:774–87. 756
- 788 [101] Wise AK, Tu T, Atkinson PJ, Flynn BO, Sgro BE, Hume
789 C, et al. The effect of deafness duration on neurotrophin
790 gene therapy for spiral ganglion neuron protection. *Hear Res*
791 2011;278:69–76. 757
- 792 [102] Iwai K, Nakagawa T, Endo T, Matsuoka Y, Kita T, Kim
793 TS, et al. Cochlear protection by local insulin-like growth
794 factor-1 application using biodegradable hydrogel.
795 *Laryngoscope* 2006;116:529–33. 758
- 796 [103] Lee KY, Nakagawa T, Okano T, Hori R, Ono K, Tabata
797 Y, et al. Novel therapy for hearing loss: delivery of insulin-like
798 growth factor 1 to the cochlea using gelatin hydrogel. *Otol
799 Neurotol* 2007;28:976–81. 759
- 800 [104] Nakagawa T, Sakamoto T, Hiraumi H, Kikkawa YS,
801 Yamamoto N, Hamaguchi K, et al. Topical insulin-like
802 growth factor 1 treatment using gelatin hydrogels for
803 glucocorticoid-resistant sudden sensorineural hearing loss:
804 a prospective clinical trial. *BMC Med* 2010;8:76. 760